National Vaccine
Information Center

Your Health. Your Family. Your Choice.

MedAlerts Home
Search Results

This is VAERS ID 508908

History of Changes from the VAERS Wayback Machine

First Appeared on 3/14/2014

VAERS ID: 508908
VAERS Form:
Age:14.0
Sex:Female
Location:Foreign
Vaccinated:2012-03-06
Onset:2012-03-06
Submitted:2013-10-22
Entered:2013-10-22
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS - / 2 UN / IM

Administered by: Other      Purchased by: Other
Symptoms: Disturbance in attention, Dizziness, Injection site pain, Malaise, Mental impairment, Nasopharyngitis, Nausea, Urticaria

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0931152A

Write-up: This case was reported by a physician and described the occurrence of thinking reduced in a 16-year-old female subject who was vaccinated with CERVARIX (GlaxoSmithKline). Historic vaccination included 1st and 2nd dose of CERVARIX (.5 ml, intramuscular; unknown site of injection and batch number) given in 2011. On 6 March 2012, the subject received 3rd dose of CERVARIX (.5 ml, intramuscular, unknown site of injection at the left side and batch number). On 6 March 2012, during vaccination with CERVARIX, the subject experienced injection site pain. One year after the vaccination with the third dose of CERVARIX, the subject presented with common cold and visited the hospital. On 3 October 2013, the subject presented with urticaria and visited the hospital. On 10 October 2013, the subject visited the hospital and presented with giddiness and malaise. On 11 October 2013, the subject presented with the giddiness and queasy. Furthermore, the subject recently complaint that she was not able to concentrate on her study and her academic performance had declined (reduced thinking). The physician considered the events were clinically significant (or requiring intervention). At the time of reporting the outcome of the events was unspecified. The physician considered that urticaria was unrelated to vaccination with CERVARIX.


Changed on 9/14/2017

VAERS ID: 508908 Before After
VAERS Form:(blank) 1
Age:14.0
Sex:Female
Location:Foreign
Vaccinated:2012-03-06
Onset:2012-03-06
Submitted:2013-10-22
Entered:2013-10-22
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS - / 2 3 UN / IM

Administered by: Other      Purchased by: Other
Symptoms: Disturbance in attention, Dizziness, Injection site pain, Malaise, Mental impairment, Nasopharyngitis, Nausea, Urticaria

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0931152A

Write-up: This case was reported by a physician and described the occurrence of thinking reduced in a 16-year-old female subject who was vaccinated with CERVARIX (GlaxoSmithKline). Historic vaccination included 1st and 2nd dose of CERVARIX (.5 ml, intramuscular; unknown site of injection and batch number) given in 2011. On 6 March 2012, the subject received 3rd dose of CERVARIX (.5 ml, intramuscular, unknown site of injection at the left side and batch number). On 6 March 2012, during vaccination with CERVARIX, the subject experienced injection site pain. One year after the vaccination with the third dose of CERVARIX, the subject presented with common cold and visited the hospital. On 3 October 2013, the subject presented with urticaria and visited the hospital. On 10 October 2013, the subject visited the hospital and presented with giddiness and malaise. On 11 October 2013, the subject presented with the giddiness and queasy. Furthermore, the subject recently complaint that she was not able to concentrate on her study and her academic performance had declined (reduced thinking). The physician considered the events were clinically significant (or requiring intervention). At the time of reporting the outcome of the events was unspecified. The physician considered that urticaria was unrelated to vaccination with CERVARIX.


Changed on 2/14/2018

VAERS ID: 508908 Before After
VAERS Form:1
Age:14.0
Sex:Female
Location:Foreign
Vaccinated:2012-03-06
Onset:2012-03-06
Submitted:2013-10-22
Entered:2013-10-22
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS - / 3 UN / IM

Administered by: Other      Purchased by: Other
Symptoms: Disturbance in attention, Dizziness, Injection site pain, Malaise, Mental impairment, Nasopharyngitis, Nausea, Urticaria

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0931152A

Write-up: This case was reported by a physician and described the occurrence of thinking reduced in a 16-year-old female subject who was vaccinated with CERVARIX (GlaxoSmithKline). Historic vaccination included 1st and 2nd dose of CERVARIX (.5 ml, intramuscular; unknown site of injection and batch number) given in 2011. On 6 March 2012, the subject received 3rd dose of CERVARIX (.5 ml, intramuscular, unknown site of injection at the left side and batch number). On 6 March 2012, during vaccination with CERVARIX, the subject experienced injection site pain. One year after the vaccination with the third dose of CERVARIX, the subject presented with common cold and visited the hospital. On 3 October 2013, the subject presented with urticaria and visited the hospital. On 10 October 2013, the subject visited the hospital and presented with giddiness and malaise. On 11 October 2013, the subject presented with the giddiness and queasy. Furthermore, the subject recently complaint that she was not able to concentrate on her study and her academic performance had declined (reduced thinking). The physician considered the events were clinically significant (or requiring intervention). At the time of reporting the outcome of the events was unspecified. The physician considered that urticaria was unrelated to vaccination with CERVARIX.


Changed on 6/14/2018

VAERS ID: 508908 Before After
VAERS Form:1
Age:14.0
Sex:Female
Location:Foreign
Vaccinated:2012-03-06
Onset:2012-03-06
Submitted:2013-10-22
Entered:2013-10-22
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS - / 3 UN / IM

Administered by: Other      Purchased by: Other
Symptoms: Disturbance in attention, Dizziness, Injection site pain, Malaise, Mental impairment, Nasopharyngitis, Nausea, Urticaria

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0931152A

Write-up: This case was reported by a physician and described the occurrence of thinking reduced in a 16-year-old female subject who was vaccinated with CERVARIX (GlaxoSmithKline). Historic vaccination included 1st and 2nd dose of CERVARIX (.5 ml, intramuscular; unknown site of injection and batch number) given in 2011. On 6 March 2012, the subject received 3rd dose of CERVARIX (.5 ml, intramuscular, unknown site of injection at the left side and batch number). On 6 March 2012, during vaccination with CERVARIX, the subject experienced injection site pain. One year after the vaccination with the third dose of CERVARIX, the subject presented with common cold and visited the hospital. On 3 October 2013, the subject presented with urticaria and visited the hospital. On 10 October 2013, the subject visited the hospital and presented with giddiness and malaise. On 11 October 2013, the subject presented with the giddiness and queasy. Furthermore, the subject recently complaint that she was not able to concentrate on her study and her academic performance had declined (reduced thinking). The physician considered the events were clinically significant (or requiring intervention). At the time of reporting the outcome of the events was unspecified. The physician considered that urticaria was unrelated to vaccination with CERVARIX.


Changed on 8/14/2018

VAERS ID: 508908 Before After
VAERS Form:1
Age:14.0
Sex:Female
Location:Foreign
Vaccinated:2012-03-06
Onset:2012-03-06
Submitted:2013-10-22
Entered:2013-10-22
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS - / 3 UN / IM

Administered by: Other      Purchased by: Other
Symptoms: Disturbance in attention, Dizziness, Injection site pain, Malaise, Mental impairment, Nasopharyngitis, Nausea, Urticaria

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0931152A

Write-up: This case was reported by a physician and described the occurrence of thinking reduced in a 16-year-old female subject who was vaccinated with CERVARIX (GlaxoSmithKline). Historic vaccination included 1st and 2nd dose of CERVARIX (.5 ml, intramuscular; unknown site of injection and batch number) given in 2011. On 6 March 2012, the subject received 3rd dose of CERVARIX (.5 ml, intramuscular, unknown site of injection at the left side and batch number). On 6 March 2012, during vaccination with CERVARIX, the subject experienced injection site pain. One year after the vaccination with the third dose of CERVARIX, the subject presented with common cold and visited the hospital. On 3 October 2013, the subject presented with urticaria and visited the hospital. On 10 October 2013, the subject visited the hospital and presented with giddiness and malaise. On 11 October 2013, the subject presented with the giddiness and queasy. Furthermore, the subject recently complaint that she was not able to concentrate on her study and her academic performance had declined (reduced thinking). The physician considered the events were clinically significant (or requiring intervention). At the time of reporting the outcome of the events was unspecified. The physician considered that urticaria was unrelated to vaccination with CERVARIX.


Changed on 9/14/2018

VAERS ID: 508908 Before After
VAERS Form:1
Age:14.0
Sex:Female
Location:Foreign
Vaccinated:2012-03-06
Onset:2012-03-06
Submitted:2013-10-22
Entered:2013-10-22
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS - / 3 UN / IM

Administered by: Other      Purchased by: Other
Symptoms: Disturbance in attention, Dizziness, Injection site pain, Malaise, Mental impairment, Nasopharyngitis, Nausea, Urticaria

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0931152A

Write-up: This case was reported by a physician and described the occurrence of thinking reduced in a 16-year-old female subject who was vaccinated with CERVARIX (GlaxoSmithKline). Historic vaccination included 1st and 2nd dose of CERVARIX (.5 ml, intramuscular; unknown site of injection and batch number) given in 2011. On 6 March 2012, the subject received 3rd dose of CERVARIX (.5 ml, intramuscular, unknown site of injection at the left side and batch number). On 6 March 2012, during vaccination with CERVARIX, the subject experienced injection site pain. One year after the vaccination with the third dose of CERVARIX, the subject presented with common cold and visited the hospital. On 3 October 2013, the subject presented with urticaria and visited the hospital. On 10 October 2013, the subject visited the hospital and presented with giddiness and malaise. On 11 October 2013, the subject presented with the giddiness and queasy. Furthermore, the subject recently complaint that she was not able to concentrate on her study and her academic performance had declined (reduced thinking). The physician considered the events were clinically significant (or requiring intervention). At the time of reporting the outcome of the events was unspecified. The physician considered that urticaria was unrelated to vaccination with CERVARIX.


Changed on 10/14/2018

VAERS ID: 508908 Before After
VAERS Form:1
Age:14.0
Sex:Female
Location:Foreign
Vaccinated:2012-03-06
Onset:2012-03-06
Submitted:2013-10-22
Entered:2013-10-22
Vaccin­ation / Manu­facturer Lot / Dose Site / Route
HPV2: HPV (CERVARIX) / GLAXOSMITHKLINE BIOLOGICALS - / 3 UN / IM

Administered by: Other      Purchased by: Other
Symptoms: Disturbance in attention, Dizziness, Injection site pain, Malaise, Mental impairment, Nasopharyngitis, Nausea, Urticaria

Life Threatening? No
Birth Defect? No
Died? No
Permanent Disability? No
Recovered? No
Office Visit (V2.0)? No
ER or Office Visit (V1.0)? No
ER or ED Visit (V2.0)? No
Hospitalized? No
Previous Vaccinations:
Other Medications:
Current Illness: Unknown
Preexisting Conditions:
Allergies:
Diagnostic Lab Data: UNK
CDC 'Split Type': B0931152A

Write-up: This case was reported by a physician and described the occurrence of thinking reduced in a 16-year-old female subject who was vaccinated with CERVARIX (GlaxoSmithKline). Historic vaccination included 1st and 2nd dose of CERVARIX (.5 ml, intramuscular; unknown site of injection and batch number) given in 2011. On 6 March 2012, the subject received 3rd dose of CERVARIX (.5 ml, intramuscular, unknown site of injection at the left side and batch number). On 6 March 2012, during vaccination with CERVARIX, the subject experienced injection site pain. One year after the vaccination with the third dose of CERVARIX, the subject presented with common cold and visited the hospital. On 3 October 2013, the subject presented with urticaria and visited the hospital. On 10 October 2013, the subject visited the hospital and presented with giddiness and malaise. On 11 October 2013, the subject presented with the giddiness and queasy. Furthermore, the subject recently complaint that she was not able to concentrate on her study and her academic performance had declined (reduced thinking). The physician considered the events were clinically significant (or requiring intervention). At the time of reporting the outcome of the events was unspecified. The physician considered that urticaria was unrelated to vaccination with CERVARIX.

New Search

Link To This Search Result:

https://www.medalerts.org/vaersdb/findfield.php?IDNUMBER=508908&WAYBACKHISTORY=ON


Copyright © 2020 National Vaccine Information Center. All rights reserved.
21525 Ridgetop Circle, Suite 100, Sterling, VA 20166